Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finotonlimab (SCT-I10A) plus Docetaxel in Advanced Squamous NSCLC
NCT04171284Phase 3Terminated
- Sponsor
- Sinocelltech Group Limited
- Start
- Oct 2019
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of finotonlimab in squamous cell carcinoma of the lung (SCCL), sponsored by Sinocelltech Group Limited. Started Oct 2019; status: terminated.
02
Drugs
finotonlimab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT04171284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171284.